VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Adult participants with low or intermediate-1 risk │ Adult participants with low or intermediate-1 risk │     100 │
│ MDS                                                │ MDS                                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No previous treatment with hematopoietic growth    │ No previous treatment with hematopoietic growth    │     100 │
│ factors within 3 months prior to screening         │ factors within 3 months prior to screening         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum erythropoietin \<500 milliunits/milliliter   │ Serum erythropoietin <500 milliunits/milliliter    │     100 │
│ (mU/mL) within 14 days prior to the first dose of  │ (mU/mL) within 14 days prior to the first dose of  │         │
│ study treatment                                    │ study treatment                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically stable for at least 1 month prior to    │ Clinically stable for at least 1 month prior to    │     100 │
│ entry into the study                               │ entry into the study                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For female participants of childbearing potential  │ For female participants of childbearing potential  │     100 │
│ and male participants with partners of             │ and male participants with partners of             │         │
│ childbearing potential, agreement (by participants │ childbearing potential, agreement (by participants │         │
│ and/or partner) to use highly effective form(s) of │ and/or partner) to use highly effective form(s) of │         │
│ contraception                                      │ contraception                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindications and/or known hypersensitivity to │ Contraindications and/or known hypersensitivity to │     100 │
│ the active substance and/or any of the excipients  │ the active substance and/or any of the excipients  │         │
│ of epoetin beta treatment                          │ of epoetin beta treatment                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Poorly controlled hypertension as assessed by the  │ Poorly controlled hypertension as assessed by the  │     100 │
│ investigator                                       │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of Acute Myeloid Leukemia (AML) or high    │ History of Acute Myeloid Leukemia (AML) or high    │     100 │
│ risk for AML                                       │ risk for AML                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of another investigational drug     │ Administration of another investigational drug     │     100 │
│ within 1 month before screening or planned during  │ within 1 month before screening or planned during  │         │
│ the study period                                   │ the study period                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously documented evidence of Pure Red Cell    │ Previously documented evidence of Pure Red Cell    │     100 │
│ Aplasia (PRCA)                                     │ Aplasia (PRCA)                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptomatic anemia (hemoglobin \<10 g/dL) as       │ Symptomatic anemia (hemoglobin <10 g/dL) as        │      99 │
│ determined by investigator                         │ determined by investigator                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Require no red blood cell transfusion or dependent │ Require no red blood cell transfusion or dependent │      99 │
│ on \<4 units within 8 weeks prior to screening     │ on <4 units within 8 weeks prior to screening      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Adult participants with low or intermediate-1 risk │      34 │
│                                   │ MDS                                                │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 94.76923076923077
OverAll Ratio: 96.38461538461539
